Predictive Oncology (US:POAI)2026-03-31 20:30Financial Performance - Total revenue for fiscal year 2025 was $125,284, derived entirely from the Drug Discovery Services segment, with no revenue from the GPU compute segment as it launched in September 2025[3]. - The net loss from continuing operations for fiscal 2025 was $232.9 million, which included $152.5 million in unrealized losses on digital assets[10][12]. - The company reported cash and cash equivalents of $10.8 million as of December 31, 2025, compared to $0.6 million at the end of 2024[10][11]. Capital and Equity - The company raised $343.5 million in capital through PIPE transactions in October 2025, significantly improving its balance sheet from negative equity to $47.7 million in stockholders' equity[2][10]. Asset Management - As of December 31, 2025, the company held approximately 6.348 billion ATH tokens, with a fair market value of $24.4 million for 2.837 billion unlocked tokens[4][10]. Strategic Initiatives - Management's operational priorities for 2026 include generating initial compute services revenue and pursuing ATH staking activities to yield returns on treasury holdings[7]. - The company is exploring strategic alternatives for its Helomics Drug Discovery Services business, including potential sale or partnership options[4][7]. Market Outlook - Global AI spending is projected to reach $2.52 trillion in 2026, representing a 44% year-over-year increase, indicating a strong market opportunity for GPU compute infrastructure[5]. - The company does not provide formal financial guidance but outlines operational priorities subject to market conditions and risks associated with ATH price volatility[6][14]. Infrastructure Development - The company established access to a distributed GPU network of over 435,000 GPUs across more than 200 locations, aimed at supporting enterprise-scale AI workloads[4][15].